Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications. Combining the advantages of antibodies in binding a specific target with the capabilities of a therapeutic payload, the majority of ADCs in preclinical and clinical development are for indications in oncology and hematology, where […]

Bolt Biotherapeutics has added longtime Mayo Clinic professor Edith Perez to its C-suite as chief medical officer. Perez, who has taught at Mayo for two decades and heads its Breast Cancer Translational Genomics program, will maintain a clinical affiliation. She previously served another stint in industry, spending three years as head of US medical affairs for Genentech’s BioOncology […]

Bolt Biotherapeutics – Edith Perez was named CMO of Bolt Therapeutics. Perez has held positions within AACR, ASCO and the NCI. Perez will maintain a clinical affiliation as Professor of Medicine at the Mayo Clinic and director of the Mayo Clinic Breast Cancer Translational Genomics Program, where she has practiced for two decades. Prior to joining […]